Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE HIVES versus ZYRTEC ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE HIVES versus ZYRTEC ALLERGY.
FEXOFENADINE HYDROCHLORIDE HIVES vs ZYRTEC ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine hydrochloride is a selective peripheral H1-receptor antagonist. It blocks the action of histamine at the H1 receptor, preventing histamine-mediated symptoms such as itching, sneezing, rhinorrhea, and urticaria.
Selective peripheral histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
60 mg orally twice daily or 180 mg orally once daily
5–10 mg orally once daily; maximum dose 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is 14.4 hours (range 11–17 hours) in healthy adults. Clinically, this supports twice-daily dosing for symptomatic relief.
Terminal elimination half-life is approximately 8.3 hours (range 6–10 hours) in healthy adults, prolonged to 20–25 hours in patients with renal impairment (CrCl < 40 mL/min). No significant difference in elderly vs. young adults with normal renal function.
Approximately 95% of the dose is excreted unchanged in feces (80%) and urine (15%). Fexofenadine undergoes minimal hepatic metabolism (<5%).
Renal excretion of unchanged drug accounts for approximately 70% of elimination; approximately 10% is excreted in feces via biliary route. Total renal excretion includes both parent drug and metabolites, with cetirizine largely unchanged.
Category A/B
Category C
Antihistamine
Antihistamine